• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A.

作者信息

Chiba Masato, Togashi Yosuke, Bannno Eri, Kobayashi Yoshihisa, Nakamura Yu, Hayashi Hidetoshi, Terashima Masato, De Velasco Marco A, Sakai Kazuko, Fujita Yoshihiko, Mitsudomi Tetsuya, Nishio Kazuto

机构信息

Kindai University Faculty of Medicine, 377-2 Ohno-higashi, Osaka-Sayama, Osaka, 589-8511, Japan.

Thoracic Surgery, Kindai University Faculty of Medicine, Osaka, Japan.

出版信息

BMC Cancer. 2017 Apr 19;17(1):281. doi: 10.1186/s12885-017-3263-z.

DOI:10.1186/s12885-017-3263-z
PMID:28424065
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5395747/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f421/5395747/62a67f29bb18/12885_2017_3263_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f421/5395747/92b38b60060c/12885_2017_3263_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f421/5395747/5ee75e1cc75f/12885_2017_3263_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f421/5395747/aa1d72723c26/12885_2017_3263_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f421/5395747/62a67f29bb18/12885_2017_3263_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f421/5395747/92b38b60060c/12885_2017_3263_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f421/5395747/5ee75e1cc75f/12885_2017_3263_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f421/5395747/aa1d72723c26/12885_2017_3263_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f421/5395747/62a67f29bb18/12885_2017_3263_Fig4_HTML.jpg

相似文献

1
Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A.不可逆表皮生长因子受体酪氨酸激酶抑制剂对罕见的继发性耐药表皮生长因子受体突变L747S、D761Y和T854A的疗效。
BMC Cancer. 2017 Apr 19;17(1):281. doi: 10.1186/s12885-017-3263-z.
2
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.表皮生长因子受体突变型肺腺癌中对激酶抑制剂产生获得性耐药的新型D761Y和常见继发性T790M突变
Clin Cancer Res. 2006 Nov 1;12(21):6494-501. doi: 10.1158/1078-0432.CCR-06-1570.
3
EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.表皮生长因子受体（EGFR）突变与对不可逆嘧啶类EGFR抑制剂的耐药性
Clin Cancer Res. 2015 Sep 1;21(17):3913-23. doi: 10.1158/1078-0432.CCR-14-2789. Epub 2015 May 6.
4
The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.第三代EGFR抑制剂治疗后获得的C797S突变的等位基因背景影响对后续治疗策略的敏感性。
Clin Cancer Res. 2015 Sep 1;21(17):3924-33. doi: 10.1158/1078-0432.CCR-15-0560. Epub 2015 May 11.
5
EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.非小细胞肺癌中 EGFR 外显子 18 突变：与第一代或第三代 TKI 相比，阿法替尼或奈拉替尼增敏的分子预测因子。
Clin Cancer Res. 2015 Dec 1;21(23):5305-13. doi: 10.1158/1078-0432.CCR-15-1046. Epub 2015 Jul 23.
6
Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation.化学生物基因组学分析为研究表达 T790M 表皮生长因子受体耐药突变的肿瘤细胞中不可逆表皮生长因子受体抑制剂活性有限的原因提供了新的视角。
Cancer Res. 2010 Feb 1;70(3):868-74. doi: 10.1158/0008-5472.CAN-09-3106. Epub 2010 Jan 26.
7
MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.MET基因扩增和MET受体激活不足以预测MET与EGFR抑制剂联合使用对EGFR TKI耐药的非小细胞肺癌细胞的疗效。
PLoS One. 2015 Nov 18;10(11):e0143333. doi: 10.1371/journal.pone.0143333. eCollection 2015.
8
Establishment and biological characteristics of acquired gefitinib resistance in cell line NCI-H1975/gefinitib-resistant with epidermal growth factor receptor T790M mutation.携带表皮生长因子受体T790M突变的NCI-H1975/吉非替尼耐药细胞系中获得性吉非替尼耐药的建立及其生物学特性
Mol Med Rep. 2015 Apr;11(4):2767-74. doi: 10.3892/mmr.2014.3058. Epub 2014 Dec 8.
9
CRKL amplification is rare as a mechanism for acquired resistance to kinase inhibitors in lung cancers with epidermal growth factor receptor mutation.在具有表皮生长因子受体突变的肺癌中，CRKL扩增作为对激酶抑制剂获得性耐药的一种机制较为罕见。
Lung Cancer. 2014 Aug;85(2):147-51. doi: 10.1016/j.lungcan.2014.05.018. Epub 2014 Jun 2.
10
EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.非小细胞肺癌中 EGFR 外显子 20 插入突变：临床前数据及临床意义。
Lancet Oncol. 2012 Jan;13(1):e23-31. doi: 10.1016/S1470-2045(11)70129-2. Epub 2011 Jul 19.

引用本文的文献

1
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer.表皮生长因子受体（EGFR）突变型非小细胞肺癌不断变化的治疗格局。
Nat Rev Clin Oncol. 2025 Feb;22(2):95-116. doi: 10.1038/s41571-024-00971-2. Epub 2024 Nov 29.
2
Single molecule tracking based drug screening.基于单分子追踪的药物筛选。
Nat Commun. 2024 Oct 17;15(1):8975. doi: 10.1038/s41467-024-53432-w.
3
Bioinformatics-driven discovery of novel EGFR kinase inhibitors as anti-cancer therapeutics: In silico screening and in vitro evaluation.基于生物信息学的新型 EGFR 激酶抑制剂抗癌治疗药物的发现：计算机筛选和体外评估。

本文引用的文献

1
Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer.表皮生长因子受体（EGFR）T790M、L792F和C797S突变作为肺癌中阿法替尼获得性耐药机制的特征分析
Mol Cancer Ther. 2017 Feb;16(2):357-364. doi: 10.1158/1535-7163.MCT-16-0407. Epub 2016 Dec 2.
2
Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer.罗西替尼用于表皮生长因子受体突变的非小细胞肺癌治疗
N Engl J Med. 2015 Aug 6;373(6):578-9. doi: 10.1056/NEJMc1506831.
3
EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.
PLoS One. 2024 Apr 16;19(4):e0298326. doi: 10.1371/journal.pone.0298326. eCollection 2024.
4
Durable response to osimertinib in an advanced lung adenocarcinoma patient with an uncommon EGFR T854A mutation: A case report.奥希替尼治疗罕见 EGFR T854A 突变晚期肺腺癌患者获得持久缓解：一例报告。
Medicine (Baltimore). 2022 Dec 9;101(49):e31875. doi: 10.1097/MD.0000000000031875.
5
Drug resistance mechanisms and progress in the treatment of EGFR-mutated lung adenocarcinoma.表皮生长因子受体（EGFR）突变型肺腺癌的耐药机制及治疗进展
Oncol Lett. 2022 Sep 26;24(5):408. doi: 10.3892/ol.2022.13528. eCollection 2022 Nov.
6
Durable response to afatinib rechallenge in a long-term survivor of non-small cell lung cancer harboring EGFR L858R and L747V mutations.在一位 EGFR L858R 和 L747V 突变的非小细胞肺癌长期幸存者中，阿法替尼再挑战获得持久缓解。
Thorac Cancer. 2022 Nov;13(22):3225-3228. doi: 10.1111/1759-7714.14678. Epub 2022 Oct 4.
7
[Targeted Therapy and Mechanism of Drug Resistance in Non-small Cell Lung Cancer 
with Epidermal Growth Factor Receptor Gene Mutation].[表皮生长因子受体基因突变的非小细胞肺癌的靶向治疗与耐药机制]
Zhongguo Fei Ai Za Zhi. 2022 Mar 20;25(3):183-192. doi: 10.3779/j.issn.1009-3419.2022.101.05.
8
Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy.非小细胞肺癌的治疗进展：聚焦于靶向治疗和免疫治疗的临床开发
MedComm (2020). 2021 Dec 14;2(4):692-729. doi: 10.1002/mco2.105. eCollection 2021 Dec.
9
Comparison of Resistance Spectra after First and Second Line Osimertinib Treatment Detected by Liquid Biopsy.通过液体活检检测的一线和二线奥希替尼治疗后耐药谱的比较。
Cancers (Basel). 2021 Jun 8;13(12):2861. doi: 10.3390/cancers13122861.
10
Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review.表皮生长因子受体表达与非小细胞肺癌靶向治疗耐药模式：综述。
Cells. 2021 May 14;10(5):1206. doi: 10.3390/cells10051206.
非小细胞肺癌中 EGFR 外显子 18 突变：与第一代或第三代 TKI 相比，阿法替尼或奈拉替尼增敏的分子预测因子。
Clin Cancer Res. 2015 Dec 1;21(23):5305-13. doi: 10.1158/1078-0432.CCR-15-1046. Epub 2015 Jul 23.
4
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.阿法替尼治疗携带非典型 EGFR 突变的晚期非小细胞肺癌患者的临床活性：LUX-Lung 2、LUX-Lung 3 和 LUX-Lung 6 的联合事后分析。
Lancet Oncol. 2015 Jul;16(7):830-8. doi: 10.1016/S1470-2045(15)00026-1. Epub 2015 Jun 4.
5
Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.对抗癌症耐药性：突变特异性 EGFR 抑制剂的机遇与挑战。
Drug Resist Updat. 2015 May;20:12-28. doi: 10.1016/j.drup.2015.05.002. Epub 2015 May 12.
6
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.阿法替尼治疗表皮生长因子受体抑制剂耐药的非小细胞肺癌
N Engl J Med. 2015 Apr 30;372(18):1689-99. doi: 10.1056/NEJMoa1411817.
7
MEK inhibitor for gastric cancer with MEK1 gene mutations.用于具有 MEK1 基因突变的胃癌的 MEK 抑制剂。
Mol Cancer Ther. 2014 Dec;13(12):3098-106. doi: 10.1158/1535-7163.MCT-14-0429. Epub 2014 Sep 24.
8
Comprehensive molecular profiling of lung adenocarcinoma.肺腺癌的全面分子分析。
Nature. 2014 Jul 31;511(7511):543-50. doi: 10.1038/nature13385. Epub 2014 Jul 9.
9
Acquired resistance to TKIs in solid tumours: learning from lung cancer.实体瘤中对 TKI 的获得性耐药：从肺癌中学习。
Nat Rev Clin Oncol. 2014 Aug;11(8):473-81. doi: 10.1038/nrclinonc.2014.104. Epub 2014 Jul 1.
10
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.AZD9291是一种不可逆的表皮生长因子受体酪氨酸激酶抑制剂（EGFR TKI），可克服T790M介导的肺癌对EGFR抑制剂的耐药性。
Cancer Discov. 2014 Sep;4(9):1046-61. doi: 10.1158/2159-8290.CD-14-0337. Epub 2014 Jun 3.